Početna stranicaM1RN34 • BVMF
add
Moderna Inc Bdr
Preth. zaklj. cijena
7,36 R$
Dnevni raspon
7,05 R$ - 7,36 R$
Godišnji raspon
6,22 R$ - 16,42 R$
Tržišna kapitalizacija
10,44 mlr. USD
Prosječna količina
59,99 tis.
P/E omjer
-
Prinos dividende
-
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 142,00 mil. | −41,08 % |
Operativni troškovi | 230,00 mil. | −14,18 % |
Neto dohodak | −825,00 mil. | 35,50 % |
Neto profitabilnost | −580,99 | −9,47 % |
Zarada po dionici | −2,13 | 36,04 % |
EBITDA | −850,00 mil. | 35,70 % |
Efektivna porezna stopa | −0,86 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 5,13 mlr. | −39,55 % |
Ukupna imovina | 12,01 mlr. | −23,41 % |
Ukupne obveze | 2,61 mlr. | −34,20 % |
Ukupni kapital | 9,40 mlr. | — |
Dionice u optjecaju | 389,08 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,30 | — |
Povrat imovine | −18,35 % | — |
Povrat kapitala | −21,65 % | — |
Tok novca
Neto promjena novca
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −825,00 mil. | 35,50 % |
Gotovina od poslovanja | −919,00 mil. | 27,86 % |
Gotovina iz ulaganja | 564,00 mil. | −65,80 % |
Gotovina iz financiranja | 9,00 mil. | −73,53 % |
Neto promjena novca | −345,00 mil. | −184,35 % |
Slobodan tok novca | −664,50 mil. | 33,39 % |
Više
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. Wikipedia
Glavni izvršni direktor
Osnovano
ruj 2010
Web-lokacija
Zaposlenici
5.800